Abcg2 Overexpression and Resistance to Danusertib in Chronic Myeloid Leukemia
Author Information
Author(s): Stefan Balabanov, Artur Gontarewicz, Gunhild Keller, Laura Raddrizzani, Melanie Braig, Roberta Bosotti, Jürgen Moll, Edgar Jost, Christine Barett, Imke Rohe, Carsten Bokemeyer, Tessa L. Holyoake, Tim H. Brümmendorf
Primary Institution: Universitäres Cancer Center Hamburg (UCCH), Universitäts-Klinikum Hamburg-Eppendorf, Hamburg, Germany
Hypothesis
Is Abcg2 overexpression a mechanism for acquired resistance to Danusertib in BCR-ABL-positive cells?
Conclusion
Abcg2 overexpression is a key mechanism of resistance to Danusertib in BCR-ABL-positive cells, but combination therapy with Imatinib can reduce this resistance.
Supporting Evidence
- Danusertib effectively inhibits BCR-ABL and aurora kinases.
- Combination therapy with Imatinib significantly reduces the emergence of drug resistance.
- Overexpression of Abcg2 was identified as the predominant mechanism of resistance to Danusertib.
Takeaway
Some cancer cells can become resistant to a drug called Danusertib because they produce too much of a protein called Abcg2, but using another drug, Imatinib, can help make Danusertib work better.
Methodology
The study involved treating BCR-ABL-positive cells with Danusertib and analyzing the effects on cell viability, apoptosis, and the phosphorylation status of key proteins.
Limitations
The study was conducted in vitro, which may not fully replicate the complexity of human disease.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website